Q: Good morning 5i team,
What is 5i's view of companies that spread stock option expense across P&L categories? A company might report significant R&D expense which an investor views as a positive, until one realizes that a considerable portion of the R&D expense is related to stock options? Is that generally-accepted accounting treatment? How do companies generally handle this? How does 5i view one treatment versus another? Thank you.
What is 5i's view of companies that spread stock option expense across P&L categories? A company might report significant R&D expense which an investor views as a positive, until one realizes that a considerable portion of the R&D expense is related to stock options? Is that generally-accepted accounting treatment? How do companies generally handle this? How does 5i view one treatment versus another? Thank you.